02
AVT02
High-concentration, low-volume adalimumab biosimilar
Approved by FDA (US) in Month 20XX
Europe (EEA, UK, Switzerland, Balkans)
Canada
Australia
Saudi Arabia
Israel
Egypt
South Africa
Morocco
Peru
Bolivia
Reference Biologic: HUMIRA®
Product Information:
FDA (US)Learn more
HUMIRA® is a trademark of AbbVie Biotechnology Ltd.
